What is the prevalence of Unverricht-Lundborg Disease?

Unverricht-Lundborg disease (ULD), also known as EPM1, is a rare form of progressive myoclonus epilepsy with an estimated prevalence of approximately 1 in 20,000 to 1 in 50,000 individuals worldwide. While exact global figures are difficult to confirm, it is considered a rare genetic condition that affects males and females equally, with clinical onset typically occurring in late childhood or early adolescence.

What is the global prevalence of Unverricht-Lundborg disease?

The prevalence of Unverricht-Lundborg disease is generally estimated to be between 1 in 20,000 and 1 in 50,000 in the general population, though these figures vary significantly by region. Because Unverricht-Lundborg disease is a recessive disorder, it is significantly more common in populations with a higher frequency of the causative CSTB gene mutation. Due to the rarity of the condition and the potential for misdiagnosis as other forms of epilepsy, these prevalence estimates should be viewed as approximations rather than absolute counts.

Are there geographic or demographic patterns in Unverricht-Lundborg disease?

Epidemiological data indicates that Unverricht-Lundborg disease shows distinct geographic clustering. It is particularly well-documented in Finland and parts of the Mediterranean, where founder effects have led to higher rates of the condition. Key demographic and clinical characteristics include:

• Gender Distribution: Unverricht-Lundborg disease affects males and females with equal frequency.


• Age of Onset: Symptoms most commonly appear between the ages of 6 and 15 years.


• Inheritance: It follows an autosomal recessive pattern, meaning both parents must carry the gene mutation for a child to be affected.


• Community Insight: Currently, 19 individuals living with Unverricht-Lundborg disease have joined the DiseaseMaps.org community, providing a valuable real-world perspective on the diagnostic journey and daily challenges of this condition.

Why is accurate data for Unverricht-Lundborg disease challenging to obtain?

Obtaining precise epidemiological data for Unverricht-Lundborg disease is difficult due to several factors, including underdiagnosis in regions with limited access to genetic testing and the potential for clinical overlap with other progressive myoclonic epilepsies. Many patients may spend years seeking a definitive diagnosis, leading to an under-representation of the true number of people living with Unverricht-Lundborg disease in global registries.

Next steps

• Consult a neurologist or epileptologist to discuss genetic testing if you suspect a diagnosis.


• Connect with the DiseaseMaps.org community to share experiences with others managing this condition.


• Review resources from the NIH GARD to stay updated on current research and potential clinical trials.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• Orphanet: Rare disease database entry for Unverricht-Lundborg disease (ORPHA:303).


• NIH Genetic and Rare Diseases Information Center (GARD): Information on EPM1.


• OMIM (Online Mendelian Inheritance in Man): Entry #254800 for Epilepsy, Progressive Myoclonic 1A.